NZ Immuno-Oncology Research Review Issue 8

In this issue:

Blinatumomab for MRD in B-cell precursor ALL
AMG 420, an anti-BCMA BITE construct, in myeloma
Emicizumab prophylaxis for haemophilia A without inhibitors
Axicabtagene ciloleucel in refractory large B-cell lymphoma
RO7082859 ±obinutuzumab in relapsed/refractory B-cell non-Hodgkin’s lymphoma
Tisagenlecleucel in relapsed/ refractory DLBCL
Second- vs. third-generation CD19-specific CAR T-cells in B-cell non-Hodgkin’s lymphoma
ASTCT grading of CRS and neurological toxicities associated with immune effector cells
Anti-BCMA CAR T-cell therapy in relapsed/refractory myeloma
Risks and benefits of CAR T-cell therapy in cancer

Please login below to download this issue (PDF)